Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.

Eiden, Adrian M; Zhang, Shuling; Gary, Joy M; Simmons, John K; Mock, Beverly A

Eiden, Adrian M; Zhang, Shuling; Gary, Joy M; Simmons, John K; Mock, Beverly A.

Affiliation

Eiden AM; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Zhang S; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Gary JM; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Simmons JK; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Mock BA; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. mockb@mail.nih.gov.

Clin Cancer Res ; 22(2): 277-83, 2016 Jan 15.

Article in En | MEDLINE | ID: mdl-26607598

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Communicable Diseases / Protein Kinase Inhibitors / Disease Susceptibility / TOR Serine-Threonine Kinases / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2016 Document type: Article Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google